Portal de Periódicos da CAPES

Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine

1987; Wiley; Volume: 49; Issue: 1 Linguagem: Inglês

10.1111/j.1471-4159.1987.tb03384.x

1471-4159

Thomas P. Singer, Neal Castagnoli, Rona R. Ramsay, Anthony J. Trevor,

Ginkgo biloba and Cashew Applications

Journal of NeurochemistryVolume 49, Issue 1 p. 1-8 Biochemical Events in the Development of Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Thomas P. Singer, Corresponding Author Thomas P. Singer Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Departments of Biochemistry and Biophysics, Molecular Biology Division (Dept. 151-S), Veterans Administration Medical Center, 4150 Clement Street, San Francisco, CA 94109, U.S.A.Search for more papers by this authorNeal Castagnoli Jr., Neal Castagnoli Jr. Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorRona R. Ramsay, Rona R. Ramsay Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorAnthony J. Trevor, Anthony J. Trevor Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this author Thomas P. Singer, Corresponding Author Thomas P. Singer Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Departments of Biochemistry and Biophysics, Molecular Biology Division (Dept. 151-S), Veterans Administration Medical Center, 4150 Clement Street, San Francisco, CA 94109, U.S.A.Search for more papers by this authorNeal Castagnoli Jr., Neal Castagnoli Jr. Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorRona R. Ramsay, Rona R. Ramsay Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorAnthony J. Trevor, Anthony J. Trevor Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this author First published: July 1987 https://doi.org/10.1111/j.1471-4159.1987.tb03384.xCitations: 205Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Baker J. K., Borne R. R., Davis M. M., and Waters I. W. (1984) Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse liver preparations. Biochem. Biophys. Res. Commun. 125, 484–490. Beinert H., Palmer G., Cremona T., and Singer T. P. (1965) Kinetic studies on reduced diphosphopyridine nucleotide dehydrogenase by electron paramagnetic resonance spectroscopy. J. Biol. Chem. 240, 475–480. Bradbury A. J., Costall B., Domeney A. M., Jenner P., Kelly M. E., Marsden C. D., and Naylor R. J. (1986) 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 319, 56–57. Cashman J. R. and Zeigler D. M. (1986) Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Mol. Pharmacol. 29, 163–167. Chiba K., Trevor A., and Castagnoli N. Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574–578. Chiba K., Trevor A. J., and Castagnoli N. Jr (1985) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128, 1228–1232. D'Amato R. J., Lipman Z. P., and Snyder S. H. (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231, 987–989. Di Monte D., Sandy M. S., Ekstrom G., and Smith M. T. (1986a) Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine toxicity. Biochem. Biophys. Res. Commun. 137, 303–309. Di Monte D., Jewell S. A., Ekstrom G., Sandy M. S., and Smith M. T. (1986b) 1-Methyl-4-phenyl-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137, 310–315. Fritz R. R., Abell C. W., Patel N. T., Gessner W., and Brossi A. (1985) Metabolism of the neurotoxin MPTP by human liver monoamine oxidase B. FEBS Lett. 186, 224–227. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467–469. Heikkila R. E., Nicklas W. J., and Duvoisin R. C. (1985) Dopaminergic toxicity after stereotaxic administration of the 1-methyl-4-pyridiniumion (MPP+) to rats. Neurosci. Lett. 59, 135–140. Morgan D. J., Singer T. P., and Casida J. E. (1968) Binding sites of rotenone, piericidin A., and Amytal in the respiratory chain. J. Biol. Chem. 243, 834–843. Irwin I. and Langston J. W. (1985) Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity Life Sci. 36, 207–212. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyM-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173–2177. Johannessen J. N., Chiueh C. C., Burns R. S., and Markey S. P. (1985a) Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36, 219–224. Johannessen J. N., Adams J. D., Schuller H. M., Bacon J. B., and Markey S. P. (1985b) 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci. 38, 743–749. Kowal A. T., Morningstar J. E., Johnson M. K., Ramsay R. R., and Singer T. P. (1986) Spectroscopic characterization of the number and type of iron-sulfur clusters in NADH-ubiquinone oxidoreductase. J. Biol. Chem. 261, 9239–9245. Langston J. W., Ballard P., Tetrud J. W., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperi-dine-analog synthesis. Science 219, 979–980. Langston J. W., Irwin I., Langston E. B., and Forno L. S. (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480–1482. Markey J. P., Johannessen J. N., Chiueh C. C., Burns R. S., and Herkenham M. A. (1984) Intra-neuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464–467. Melamed E., Rosenthal J., Cohen O., Globus M., and Uzzan A. (1985) Dopamine but not epinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur. J. Pharmacol. 116, 179–181. Mytilineou C., and Cohen G. (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science 225, 529–531. Nicklas W. J., Vyas I., and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503–2508. Peterson L. A., Caldera P. S., Trevor A., Chiba K., and Castagnoli N. Jr (1985) Studies on the 1-methyl-4-phenyl-2,3-dihydro-pyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin MPTP. J. Med. Chem. 28, 1432–1436. Poirier J. and Barbeau A. (1985) A catalyst function for MPTP in superoxide formation. Biochem. Biophys. Res. Commun. 131, 1284–1289. Poirier J., Donaldson J., and Barbeau A. (1985) The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochem. Biophys. Res. Commun. 128, 25–33. Ramsay R. R., and Singer T. P. (1986) Energy-dependent uptake of Af-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7585–7587. Ramsay R. R., Salach J. L., and Singer T. P. (1986a) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) and its relation to the inhibition of mitochondrial NADH-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 134, 743–748. Ramsay R. R., Salach J. L., Dadgar J., and Singer T. P. (1986b) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135, 269–275. Ramsay R. R., Dadgar J., Trevor A. J., and Singer T. P. (1986c) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581–588. Ramsay R. R., Salach J. L., McKeown K., Johnson M. K., Kowal A. T., Johnson A. E., Booth R., and Singer T. P. (1987) Action of pyridine derivatives on mitochondrial respiration and NADH dehydrogenase and their carrier-mediated uptake into mitochondria. Biochem. Biophys. Res. Commun. (in press). Salach J. I., Singer T. P., Castagnoli N. Jr, and Trevor A. (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun. 125, 831–835. Sayre L. M., Arora P. K., Feke S. C., and Urbach F. L. (1986) Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analogue of a postulated toxic metabolite. J. Am. Chem. Soc. 108, 2464–2466. Schmidt C. J., Bruckwick E., and Lovenberg W. (1985) Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Eur. J. Pharmacol. 113, 149–150. Singer T. P., Salach J. I., and Crabtree D. (1985) Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Biophys. Res. Commun. 127, 341–346. Singer T. P., Salach J. I., Castagnoli N. Jr, and Trevor A. J. (1986) Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem. J. 235, 785–789. SnyderS. H. and D'Amato R. J. (1985) Predicting Parkinson's disease. Nature 317, 198–199. Sundstrom E. and Jonnson G. (1985) Pharmacological interference with the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholaminergic neurons in the mouse. Eur. J. Pharmacol. 110, 293–299. Trevor A. J., Castagnoli N. Jr, and Singer T. P. (1987) Pharmacology and toxicology of MPTP: a neurotoxic by-product of illicit designer drug chemistry, in Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology and Behavior ( K. Redda, C. A. Walker, G. Barnett, and L. D. Fannin), in press. CRC Press, Boca Raton , Florida . Weissman J., Trevor A. J., Chiba K., Peterson L. A., Caldera P., and Castagnoli N. Jr (1985) Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28, 997–1001. Westlund K. N., Denney R. M., Kochenperger L. M., Rose R. M., and Abell C. W. (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230, 181–183. Wu E. Y., Chiba K., Trevor A. J., and Castagnoli N. Jr (1986) Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin. Life Sci. 39, 1695–1700. Citing Literature Volume49, Issue1July 1987Pages 1-8 ReferencesRelatedInformation